Investigators

Find a Member

Full Investigator List

Finding the right member is just a click away.

Results

Kalil Abdullah

Kalil Abdullah

Program: Cancer Therapeutics

(215) 603-6019 abdullahkg@upmc.edu UPMC Cancer Pavilion
5150 Centre Ave
Pittsburgh PA
Summary

My laboratory is focused on developing novel clinical models of glioma and identifying druggable targets to facilitate early phase clinical trials.

Gliomas are intensely heterogenous tumors that not only contain numerous cell types, but also demonstrate the ability to transition between different phenotypic states. This complexity has made developing model systems that recapitulate human tumor biology both difficult and essential. Traditionally, models of gliomas are 2-dimensional cell lines and only represent certain subtypes of the highest-grade glioma, glioblastoma. This is because the unique biology of lower grade gliomas has prevented them from being studied either outside of the lab or in animals. We have created ex-vivo culture systems that allow us to investigate critical aspects of the tumor microenvironment, immune response, and discover targets for therapy. Our laboratory has previously shown the ability to establish lower grade glioma organoids in vitro, maintain those cultures for extended periods of time, hibernate, and then reanimate tumor tissue without loss of either genetic or phenotypic fidelity. Our work also includes extensive and sophisticated live-cell imaging analysis that allows for longitudinal, non-invasive assessment of organoid response to treatment.
Our organoid model systems, in addition to glioma stem cell and mouse models, allow us to perform highly sophisticated assessments of drug response across platforms, and identify rare but critical druggable targets in gliomas. These analyses include complex metabolic tracing and immune cell response assessment. Despite the fundamental principles of genomics, immunology, and cellular cancer biology that underlie our work, our group focuses on projects that have high potential for immediate clinical translation.

Read More about Kalil Abdullah
Sameer Agnihotri

Sameer Agnihotri

Program: Cancer Biology

(412) 218-8456 sameer.agnihotri@pitt.edu Rangos Research Center, Room 7126
4401 Penn Avenue
Pittsburgh PA
Summary

The lab has a focus on several topics:
1) It is now appreciated that HGG glioma comprises of several molecular subgroups and that the genetics of pediatric and adult HGG are distinct. Therefore a “one size that fits all” approach to therapy will not be successful. The Agnihotri Laboratory interests include using next-generation sequencing technology to identify and validate driver alterations of various HGG with a focus on DIPG and non-histone mutated “RTK” Glioblastoma (GBM). 
2) A defining hallmark of glioblastoma and DIPG is altered tumor metabolism. The metabolic shift towards aerobic glycolysis with reprogramming of mitochondrial oxidative phosphorylation, regardless of oxygen availability, is a phenomenon known as the Warburg effect. In addition to the Warburg effect, glioblastoma tumor cells also utilize the tricarboxylic acid cycle/oxidative phosphorylation in a different capacity than normal tissue. The Agnihotri Laboratory investigates the metabolic dependencies of brain tumors and if they can provide therapeutic vulnerabilities.
3) The lab uses the genomic and metabolic information to build better representative brain tumor pre-clinical models for testing of novel therapies. Working closely with a clinical team use of these accurate models are essential to start early phase clinical trials.

Read More about Sameer Agnihotri
Katherine Aird

Katherine Aird

Program: Cancer Biology

airdk@upmc.edu The Assembly
5051 Centre Ave
Pittsburgh PA
Summary

The central theme of my research program is to investigate the metabolic and epigenetic control of senescence in the context of cancer. Cellular senescence is a stable cell cycle arrest that can be both tumor suppressive and tumor promoting in a highly context-dependent manner. Relatively little is known about metabolic changes that either induce or inhibit senescence. Using a combination of cell and molecular biology tools in addition to high-throughput approaches such as metabolomics and functional (epi)-genomics, my laboratory aims to mechanistically understand how to induce or overcome senescence. Our studies also include aspects of translational research utilizing both ovarian cancer and melanoma models to explore whether these newly-identified metabolic and epigenetic pathways can be targeted for novel cancer therapies. The lab is currently funded by: 1) an NCI R37 MERIT Award to understand pro-tumorigenic nucleotide metabolism in melanomagenesis; 2) an American Cancer Society Research Scholar Grant to investigate the role of isocitrate dehydrogenase 1 (IDH1)-mediated alpha-ketoglutarate production in histone methylation at homologous recombination genes in ovarian cancer; and 3) 2 NRSA F31s elucidating various metabolic and epigenetic mechanisms in ovarian cancer senescence. Pending grants include the role of nuclear acetyl-CoA production on histone acetylation and DNA damage response in ovarian cancer (NCI mPI R01) and how macropinocytosis of branched chain amino acids affects both tumor cell-intrinsic and immune cell responses to therapy (DoD Ovarian Cancer Research Program, a collaboration with Dr. Greg Delgoffe).

Read More about Katherine Aird
Oleg Akilov

Oleg Akilov

Program: Cancer Immunology and Immunotherapy

412-647-4200 akilovoe@upmc.edu 3601 Fifth Avenue, 5th Floor
Pittsburgh PA
Summary

Oleg E. Akilov, MD, PhD, is an Assistant Professor of the Department of Dermatology at the University of Pittsburgh and a Director of the Cutaneous Lymphoma Program and Extracorporeal Photopheresis Unit. Dr. Akilov directs Cutaneous Lymphoma Program providing the full spectrum of management of all stages of cutaneous lymphoma. He serves as a principal investigator on multiple clinical trials in cutaneous lymphoma. Additionally, Dr. Akilov is very enthusiastic about resident education and mentoring future dermatologists.

Read More about Oleg Akilov
Jonathan Alder

Jonathan Alder

Program: Genome Stability

412-624-8681 alderju@upmc.edu BST W1246
200 Lothrop St.
Pittsburgh PA
Read More about Jonathan Alder
Daniel Altschuler

Daniel Altschuler

Program: Cancer Therapeutics

412-648-9751 altschul@pitt.edu Biomedical Science Tower, E-1348
200 Lothrop Street
Pittsburgh PA
Summary

Dr. Altschuler's laboratory studies mechanisms of signal transduction by the second messenger cAMP in cell proliferation. cAMP-dependent protein kinase (PKA) and Exchange protein activated by cAMP (Epac) represent the main effectors of cAMP action. Both pathways converge at the level of the small GTPase Rap1b, via its Epac-mediated activation and PKA-mediated phosphorylation. The role of Rap1 activation (Epac) and phosphorylation (PKA) coordinating the early rate-limiting events in cAMP-dependent cell proliferation are studied using a multidisciplinary approach including molecular and cellular biology techniques in vitro, as well as in vivo validation using transgenic/knock in technologies in endocrine tumor models.

Read More about Daniel Altschuler
Zandrea Ambrose

Zandrea Ambrose

Program: Cancer Virology

(412) 624-0512 zaa4@pitt.edu 450 Technology Drive
520 Bridgeside Point 2
Pittsburgh PA
Summary

Millions of people are infected with both HIV and HBV. Morbidity and mortality in HIV/HBV co-infection is higher than mono-infections and co-infection accelerates HBV-related liver disease with more frequent development of hepatocellular carcinoma (HCC), particularly when CD4 cell counts are low. Together with Dr. Haitao Guo, we will develop a murine model to study pathogenesis and HCC progression during HIV/HBV co-infection, which will be essential in evaluating mechanisms of infection as well as novel prevention methods, improved therapies, and curative strategies.

Read More about Zandrea Ambrose
Leonard Appleman

Leonard Appleman

Program: Cancer Therapeutics

412-648-6507 applemanlj@upmc.edu UPMC Cancer Pavilion
5230 Center Ave., Suite 567
Pittsburgh PA
Research Interests and Keywords
  • experimental cancer therapeutics,Kidney cancer and other genitourinary malignancies
Read More about Leonard Appleman
Karen Arndt

Karen Arndt

Program: Genome Stability

412-624-6963 arndt@pitt.edu A316 Langley Hall
4249 Fifth Ave
Pittsburgh PA
Summary

A critical question to ask, particularly in this genomic era, is how organisms interpret the vast amounts of information encoded in their genomes. The Arndt lab studies the first step in gene expression, the synthesis of mRNA by RNA polymerase II, with a focus on the mechanisms that regulate transcription in the chromatin environment of a eukaryotic cell. The fundamental importance of understanding transcriptional regulation is evident from the large number of human developmental defects and diseases, including cancer and AIDS, that arise when cellular transcription factors are altered by mutation or commandeered by viral proteins.

Research Interests and Keywords
  • cellular transcription,Chromatin,Gene Expression,mRNA synthesis,RNA polymerase II
Read More about Karen Arndt
Maninjay Atianand

Maninjay Atianand

Program: Cancer Immunology and Immunotherapy

412-383-0472 atianand@pitt.edu 200 Lothrop St
W1046 BST
Pittsburgh PA
Read More about Maninjay Atianand

View Investigators by Last Name

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Top